Morgan Stanley
MS
$210.42
+0.17%
Morgan Stanley is a global financial services firm offering investment banking, institutional trading, and wealth and asset management services. It is a market leader in wealth management with $9.3 trillion in client assets and a top-10 U.S. banking franchise by deposits. The current investor narrative centers on the firm's ability to sustain revenue growth from wealth management fees and investment banking rebound, while managing margin pressures from higher interest expenses and regulatory costs. Recent Q2 2026 earnings showed strong revenue growth of 22.4% year-over-year, driven by institutional securities and wealth management segments.…
MS
Morgan Stanley
$210.42
Related headlines
Investment Opinion: Should I buy MS Today?
Rating: Buy. Thesis: Morgan Stanley's accelerating revenue growth, expanding margins, and attractive PEG ratio of 0.60 support a Buy rating, with the consensus analyst average target of $236.33 implying 10.2% upside. The stock is well-positioned to benefit from a rebound in investment banking and continued wealth management growth.
Supporting Evidence: The trailing P/E of 17.2x is above the industry average of 15x, but the PEG ratio of 0.60 suggests undervaluation relative to earnings growth. Revenue grew 22.4% YoY in Q2 2026, accelerating from 8.7% a year ago. Gross margin improved to 61.6% from 54.7%, and operating margin expanded to 21.5% from 16.4%. Free cash flow is negative, but operating cash flow of $11.8B in Q2 2025 indicates underlying cash generation. The analyst consensus is Buy with an average target of $236.33, providing a 10.2% upside.
Risks & Conditions: The high debt-to-equity ratio of 4.26 and negative free cash flow are key risks. If revenue growth decelerates below 10% or margins contract, the stock could face multiple compression. A downgrade from Buy to Hold would be warranted if the P/E exceeds 20x without corresponding growth acceleration. Conversely, an upgrade to Strong Buy would be justified if free cash flow turns positive and debt-to-equity falls below 3.5. Overall, the stock appears fairly valued relative to its history but slightly overvalued versus peers, though the growth trajectory justifies the premium.
Sign up to view all
MS 12-Month Price Forecast
The AI assessment is bullish with medium confidence. Morgan Stanley's strong revenue acceleration, expanding margins, and attractive PEG ratio support a positive outlook. However, the high debt-to-equity ratio, negative free cash flow, and premium valuation relative to peers temper confidence. The base case of moderate growth and stable margins is most likely, with a 50% probability. The bull case (30%) could materialize if investment banking rebounds strongly, while the bear case (20%) is tied to a recession. Key factors to watch are revenue growth trajectory, margin trends, and free cash flow generation. An upgrade to high confidence would require positive free cash flow and debt reduction.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Morgan Stanley's 12-month outlook, with a consensus price target around $236.38 and implied upside of +12.3% versus the current price.
Average Target
$236.38
0 analysts
Implied Upside
+12.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$184 - $262
Analyst target range
Morgan Stanley is covered by 21 analysts, with a consensus recommendation of 'Buy' (mean rating 2.32 on a 1-5 scale where 1 is Strong Buy). The average price target is $236.33, implying approximately 10.2% upside from the current price of $214.48. The distribution leans bullish, with several recent upgrades from firms like UBS and B of A Securities maintaining Buy ratings, while a few neutral ratings from Goldman Sachs and JP Morgan suggest some caution. The target range spans from a low of $184.00 to a high of $262.00. The high target of $262 assumes continued strong earnings growth, multiple expansion, and successful execution in wealth management and investment banking. The low target of $184 reflects risks such as margin compression from higher interest expenses, a slowdown in capital markets activity, or a recession impacting fee income. The spread between low and high targets is $78 (42% of the low), indicating moderate uncertainty. Recent analyst actions show mostly reaffirmations, with one downgrade from Oppenheimer to Underperform, suggesting some divergence in views. Overall, the consensus is moderately bullish, with the average target implying a double-digit return.
Drowning in data?
Find the real signal!
Bulls vs Bears: MS Investment Factors
Morgan Stanley presents a compelling growth story with accelerating revenue, expanding margins, and a consensus Buy rating from analysts. The stock's PEG ratio of 0.60 suggests undervaluation relative to earnings growth, while the 10.2% upside to the average analyst target offers moderate return potential. However, the high debt-to-equity ratio, negative free cash flow, and premium valuation relative to peers introduce risks. The single most important tension is whether the strong revenue growth and margin expansion can continue to justify the premium valuation, especially if capital markets activity slows or interest expenses rise. Currently, the bull case has stronger evidence given the robust fundamental momentum and analyst support, but the bear case warrants caution due to elevated valuation and financial leverage.
Bullish
- Strong Revenue Acceleration: Q2 2026 revenue grew 22.4% YoY to $34.47B, accelerating from 8.7% growth in the prior-year quarter, driven by wealth management and investment banking.
- Expanding Profit Margins: Gross margin improved to 61.6% from 54.7% a year ago, and operating margin expanded to 21.5% from 16.4%, reflecting operating leverage and cost control.
- Attractive PEG Ratio: With a PEG ratio of 0.60, the stock appears undervalued relative to its earnings growth rate, as a PEG below 1.0 typically signals undervaluation.
- Analyst Consensus Buy: 21 analysts rate the stock a Buy with an average price target of $236.33, implying 10.2% upside from the current price of $214.48.
Bearish
- High Debt-to-Equity Ratio: The debt-to-equity ratio of 4.26 is high, typical for a bank holding company, but increases financial risk and interest expense sensitivity.
- Negative Free Cash Flow: Trailing twelve-month free cash flow is negative $1.05B, largely due to working capital swings from securities financing activities, which could pressure capital returns.
- Near 52-Week High: At $214.48, the stock is at 92.4% of its 52-week high of $232.25, suggesting limited upside potential and risk of pullback after a 50.5% annual gain.
- Valuation Premium to Peers: The trailing P/E of 17.2x and P/B of 2.50x are above industry averages of 15x and 1.8x, respectively, indicating a premium that may compress if growth slows.
MS Technical Analysis
Morgan Stanley is in a sustained uptrend, with the stock up 50.5% over the past year, significantly outperforming the S&P 500's 16.5% gain. The current price of $214.48 sits at 92.4% of its 52-week range ($136.17–$232.25), indicating the stock is near the top of its range, reflecting strong momentum but also potential overextension. The 1-year relative strength versus SPY is +34.0%, confirming the stock's leadership in the financial sector. Short-term momentum shows a mixed picture: the stock gained 14.0% over the past 3 months but declined 2.4% in the last month, suggesting a short-term pullback. This divergence between the 1-month decline and the strong 1-year trend could signal a temporary consolidation or profit-taking after a sustained rally, rather than a trend reversal. The 3-month relative strength of +10.5% versus SPY indicates the stock still holds an edge over the market over the medium term. The 52-week high of $232.25 acts as key resistance, while the 52-week low of $136.17 provides a distant support level. A breakout above $232.25 would signal continuation of the uptrend and likely attract momentum buyers, while a breakdown below the recent support near $210 (the July 20 low) could trigger further selling. The stock's beta of 1.22 implies it is 22% more volatile than the market, meaning it tends to amplify market moves, which is important for risk management.
Beta
1.22
1.22x market volatility
Max Drawdown
-19.3%
Largest decline past year
52-Week Range
$136-$232
Price range past year
Annual Return
+47.7%
Cumulative gain past year
| Period | MS Return | S&P 500 |
|---|---|---|
| 1m | -0.7% | +0.2% |
| 3m | +10.6% | +3.7% |
| 6m | +15.1% | +8.0% |
| 1y | +47.7% | +18.2% |
| ytd | +15.7% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MS Fundamental Analysis
Revenue growth has been accelerating, with Q2 2026 revenue of $34.47 billion up 22.4% year-over-year, compared to 8.7% growth in the prior-year quarter. The trailing twelve-month revenue reached $126.5 billion, driven by strong performance in Wealth Management ($8.43 billion in Q2) and Institutional Securities ($7.93 billion). The revenue trajectory is robust, supported by higher investment banking fees and asset management revenues, though interest income growth may moderate as the Fed pauses rate hikes. Net income for Q2 2026 was $5.58 billion, up 57.7% from $3.54 billion a year ago, with EPS of $3.46 versus $2.15. Gross margin improved to 61.6% from 54.7% a year ago, reflecting better revenue mix and cost control. Operating margin expanded to 21.5% from 16.4%, indicating operating leverage. The net margin of 16.2% is healthy for a capital markets firm, though slightly below the 17.0% in Q1 2026. The company is solidly profitable with a trailing ROE of 15.1%. The balance sheet shows a debt-to-equity ratio of 4.26, which is high but typical for a bank holding company. Free cash flow was negative $1.05 billion over the trailing twelve months, largely due to working capital swings from securities financing activities. However, the company generated $11.8 billion in operating cash flow in Q2 2025, and the current ratio of 1.17 suggests adequate short-term liquidity. The payout ratio of 39.1% and dividend yield of 2.36% indicate a sustainable dividend with room for growth.
Quarterly Revenue
$34.5B
2026-06
Revenue YoY Growth
+22.4%
YoY Comparison
Gross Margin
61.7%
Latest Quarter
Free Cash Flow
$-1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MS Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 17.2x, while the forward P/E is 15.8x, implying the market expects earnings growth of about 9% over the next year. The gap between trailing and forward P/E suggests modest growth expectations are already priced in. Compared to the industry average (Financial - Capital Markets), Morgan Stanley's P/E of 17.2x is at a premium to the sector median of roughly 15x, reflecting its superior profitability and market position. The P/B ratio of 2.50x is also above the industry average of 1.8x, indicating the market values its franchise and asset base highly. The PEG ratio of 0.60 suggests the stock is undervalued relative to its growth rate, as a PEG below 1.0 typically indicates undervaluation. Historically, Morgan Stanley's trailing P/E has ranged from 10.7x (Q1 2022) to 27.1x (Q4 2023), with the current 17.2x near the middle of that range. This suggests the stock is fairly valued relative to its own history, not excessively cheap nor expensive. The P/B ratio of 2.50x is near the high end of its 5-year range of 1.3x–2.5x, indicating the market is pricing in a strong return on equity and franchise value.
PE
17.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 11x~17x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
24.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Morgan Stanley's high debt-to-equity ratio of 4.26 amplifies sensitivity to interest rate changes, as interest expense of $13.1B in Q2 2026 represents a significant cost. Negative free cash flow of -$1.05B over the trailing twelve months, driven by working capital swings in securities financing, could constrain dividend growth or buybacks. Additionally, net margin of 16.2% is healthy but slightly below the 17.0% in Q1 2026, indicating potential pressure from rising costs. The payout ratio of 39.1% is sustainable, but any sustained earnings decline could threaten dividend growth.
Market & Competitive Risks: The stock's beta of 1.22 implies 22% higher volatility than the market, making it sensitive to macro shocks. The trailing P/E of 17.2x is above the industry average of 15x, leaving room for multiple compression if growth disappoints. Recent news highlights a downgrade wave for bank stocks, with analysts warning of 'priced for perfection' valuations ahead of Q2 earnings. Competitive pressure from other bulge-bracket banks and the shift to passive investing could weigh on fee income. Regulatory costs from the Fed stress tests and potential capital requirements also pose headwinds.
Worst-Case Scenario: A severe recession could trigger a sharp decline in investment banking fees and wealth management revenues, while credit losses rise. Combined with high operating leverage, this could lead to earnings falling to the analyst low estimate of $15.52 per share. Applying a bear-case P/E of 12x (near the 5-year low of 10.7x) yields a target of $186, but the 52-week low of $136.17 represents a more extreme downside of -36.5% from the current price. In this scenario, an investor could lose up to $78.31 per share, or 36.5% of their investment.
FAQ
The key risks are: 1) Financial risk from high debt-to-equity of 4.26 and negative free cash flow, which could pressure dividends or buybacks. 2) Valuation risk from a P/E of 17.2x above the industry average, leaving room for multiple compression if growth slows. 3) Macro risk from a beta of 1.22, making the stock sensitive to market downturns. 4) Competitive risk from other bulge-bracket banks and regulatory changes. The most severe risk is a recession that could cut earnings by 30% or more, potentially driving the stock to the 52-week low of $136.17.
The 12-month forecast is moderately bullish. The base case (50% probability) expects the stock to trade between $210 and $236, aligning with the analyst average target of $236.33. The bull case (30% probability) targets $236-$262, driven by strong investment banking and wealth management growth. The bear case (20% probability) sees the stock falling to $184-$210 due to a recession or margin compression. The most likely scenario is the base case, assuming continued revenue growth of 10-15% and stable margins.
Morgan Stanley's trailing P/E of 17.2x is above the industry average of 15x, suggesting a premium valuation. However, the PEG ratio of 0.60 indicates the stock is undervalued relative to its earnings growth rate, as a PEG below 1.0 is typically considered attractive. The P/B ratio of 2.50x is near the high end of its 5-year range of 1.3x-2.5x, reflecting the market's confidence in its franchise value. Overall, the stock appears fairly valued relative to its own history but slightly overvalued versus peers, though the growth trajectory justifies the premium.
Morgan Stanley is a good buy for investors with a moderate risk tolerance seeking growth and income. The stock offers a 10.2% upside to the average analyst target of $236.33, supported by strong revenue growth of 22.4% YoY and a PEG ratio of 0.60 indicating undervaluation. However, the high debt-to-equity ratio of 4.26 and negative free cash flow of -$1.05B are risks. It is best suited for long-term investors who can tolerate short-term volatility (beta 1.22) and are bullish on capital markets. For conservative investors, the premium valuation relative to peers may be a concern.
Morgan Stanley is more suitable for long-term investment (3-5 years) due to its cyclical nature and beta of 1.22. The stock has strong long-term growth drivers in wealth management and investment banking, with a dividend yield of 2.36% providing income. Short-term trading is possible given the stock's volatility, but the near 52-week high suggests limited upside in the near term. A minimum holding period of 3 years is recommended to ride out market cycles and benefit from earnings growth. The PEG ratio of 0.60 supports long-term value creation.
